Vanda ’s patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat.

The Supreme Court ruling ensures Vanda ’s ability to exclusively market the product until November 2027.

Source: bizjournals.com Health Care:Biotechnology headlines - January 16, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news